Home › Research › Treatments
Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study
Olivia K Hopkinson, Jan Chobanov, Darshna Goordeen, Kenneth K C Man, Ian C K Wong, Emily Reeve, J Simon Bell, Li Wei, et al.. The lancet. Healthy longevity, 2026-05
Topic: Risk, prevention and care in population studies
Plain-language summary
Guidelines recommend limiting antipsychotic treatment to short-term use ( Methods Using UK primary care data from the Clinical Practice Research Datalink, linked with hospital and mortality data from Jan 1, 1998, to March 31, 2021, we emulated two sets of target trials, one after 12 weeks of antipsychotic treatment and another after 24 weeks of antipsychotic treatment, to compare continuing treatment versus tapering treatment and continuing treatment versus abrupt discontinuation of treatment. Compared with continuation after 12 weeks of treatment, estimated risks of delirium and fracture under the tapering strategy corresponded to 24-month ARDs of -2·46% (95% CI -4·10 to -1·27) and -2·80% (-4·14 to -1·29), respectively. Similar results were found after 24 weeks of treatment and in sensitivity analyses.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 24,822 participants. This analysis of UK primary care data found that tapering antipsychotics after 12 weeks of treatment was linked to lower estimated risks of delirium and fracture compared with continuing treatment. Its stated limit: Observational target-trial emulation, not a randomised trial; relies on prescription records rather than confirmed drug taking; UK data from 1998-2021 may not transfer to other systems.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hopkinson, O. K., Chobanov, J., Goordeen, D., Man, K. K. C., Wong, I. C. K., Reeve, E., et al. (2026). Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study. The lancet. Healthy longevity. https://doi.org/10.1016/j.lanhl.2026.100852
Vancouver
Hopkinson OK, Chobanov J, Goordeen D, Man KKC, Wong ICK, Reeve E, et al. Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study. The lancet. Healthy longevity. 2026. doi:10.1016/j.lanhl.2026.100852. PMID: 42302797.
BibTeX
@article{hopkinson2026-42302797,
author = {Hopkinson, Olivia K and Chobanov, Jan and Goordeen, Darshna and Man, Kenneth K C and Wong, Ian C K and Reeve, Emily and Bell, J Simon and Wei, Li and others},
title = {{Abrupt discontinuation and tapering of antipsychotics in older adults with dementia: a target trial emulation study}},
journal = {The lancet. Healthy longevity},
year = {2026},
doi = {10.1016/j.lanhl.2026.100852},
pmid = {42302797},
url = {https://doi.org/10.1016/j.lanhl.2026.100852}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Guidelines recommend limiting antipsychotic treatment to short-term use (<12 weeks), followed by tapering and cessation.
- Compared with continuation after 12 weeks of treatment, estimated risks of delirium and fracture under the tapering strategy corresponded to 24-month ARDs of -2·46% (95% CI -4·10 to -1·27) and -2·80% (-4·14 to -1·29), respectively.
- Similar results were found after 24 weeks of treatment and in sensitivity analyses.
Why it matters
This analysis of UK primary care data found that tapering antipsychotics after 12 weeks of treatment was linked to lower estimated risks of delirium and fracture compared with continuing treatment. This supports guidance to limit antipsychotic use to short-term treatment in older adults with dementia.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort
- Participants24,822
- Effect sizeTapering vs continuing antipsychotic after 12 weeks: 24-month absolute risk difference -2.46% (95% CI -4.10 to -1.27) for delirium; -2.80% (-4.14 to -1.29) for fracture
- Evidence strengthModerate
Limitations
Observational target-trial emulation, not a randomised trial; relies on prescription records rather than confirmed drug taking; UK data from 1998-2021 may not transfer to other systems.
How this study scored 54/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 53 of the 98 points we could judge it on, which is 54 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The lancet. Healthy longevity) |
| Journal's citation record | 1 / 4 | The Lancet Healthy Longevity: journal h-index 78 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 24,822 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Wallis C. Y. Lau: h-index 30 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42302797) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 53 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 53 of the 98 points we could judge it on is 54 out of 100. |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.